Ibrahimhalil Dusunceli, Zeynep Gok Sargin, Umut Celik, Fatih Sargin
{"title":"The ability of C-reactive protein-albumin ratio to predict disease activity in ulcerative colitis.","authors":"Ibrahimhalil Dusunceli, Zeynep Gok Sargin, Umut Celik, Fatih Sargin","doi":"10.1080/17520363.2025.2459596","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Ulcerative colitis (UC) is an incurable disease represented by relapse and remission. Noninvasive biomarkers are required to predict disease activation. This study aimed to identify noninvasive biomarkers, such as the c-reactive protein-albumin (CRP/ALB) ratio, platelet-lymphocyte ratio (PLR), and neutrophil-lymphocyte ratio (NLR), that might forecast disease activation in UC.</p><p><strong>Methods: </strong>This retrospective study included 443 participants: 192 patients with active UC, 166 in remission, and 85 healthy controls. Mayo Endoscopic Subscore was employed to assess endoscopic disease activity. Serum CRP, erythrocyte sedimentation rate (ESR), ALB levels, and complete blood count characteristics were documented. Three ratios of inflammation-related indicators were identified as CRP/ALB, PLR, and NLR.</p><p><strong>Results: </strong>A positive correlation was found between ESR, CRP, neutrophil count, platelet count, levels of CRP/ALB, PLR, NLR, and endoscopic activity. The CRP/ALB ratio demonstrated more efficacy than the NLR and PLR in differentiating the UC patients from the controls (<i>p</i> = 0.007, <i>p</i> = 0.003, respectively) and the active group from the remission group (<i>p</i> < 0.001, <i>p</i> < 0.001, respectively). Regression analysis revealed that the CRP/ALB was significantly able to distinguish active UC from the remission group and the controls (<i>p</i> < 0.001, <i>p</i> < 0.001, respectively).</p><p><strong>Conclusion: </strong>The CRP/ALB ratio could be useful as an independent predictive biomarker for disease activity in UC.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-7"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2459596","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Ulcerative colitis (UC) is an incurable disease represented by relapse and remission. Noninvasive biomarkers are required to predict disease activation. This study aimed to identify noninvasive biomarkers, such as the c-reactive protein-albumin (CRP/ALB) ratio, platelet-lymphocyte ratio (PLR), and neutrophil-lymphocyte ratio (NLR), that might forecast disease activation in UC.
Methods: This retrospective study included 443 participants: 192 patients with active UC, 166 in remission, and 85 healthy controls. Mayo Endoscopic Subscore was employed to assess endoscopic disease activity. Serum CRP, erythrocyte sedimentation rate (ESR), ALB levels, and complete blood count characteristics were documented. Three ratios of inflammation-related indicators were identified as CRP/ALB, PLR, and NLR.
Results: A positive correlation was found between ESR, CRP, neutrophil count, platelet count, levels of CRP/ALB, PLR, NLR, and endoscopic activity. The CRP/ALB ratio demonstrated more efficacy than the NLR and PLR in differentiating the UC patients from the controls (p = 0.007, p = 0.003, respectively) and the active group from the remission group (p < 0.001, p < 0.001, respectively). Regression analysis revealed that the CRP/ALB was significantly able to distinguish active UC from the remission group and the controls (p < 0.001, p < 0.001, respectively).
Conclusion: The CRP/ALB ratio could be useful as an independent predictive biomarker for disease activity in UC.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
